We derived from blood lymphocytes of a melanoma patient a large number of cytolytic T-cell clones directed against a cell line of the autologous tumor. Three distinct groups of antigens were recognized by these CTL on the autologous melanoma cells: group A consisted of stable antigens present on all
TCR usage in CTLs recognizing melanoma/melanocyte antigens
β Scribed by Markus J. Maeurer; Dina M. Martin; Walter J. Storkus; Michael T. Lotze
- Publisher
- Elsevier Science
- Year
- 1995
- Tongue
- English
- Weight
- 457 KB
- Volume
- 16
- Category
- Article
- ISSN
- 0167-5699
No coin nor oath required. For personal study only.
π SIMILAR VOLUMES
## We have pursued our analysis of potential tumor-rejection antigens recognized on human melanoma by autologous cytolytic T lymphocytes (CTL). We reported previously that 3 distinct antigens ( A,B,C) were recognized on melanoma cell line SK29-MEL in association with HLA-A2. Selection for melanoma
Melanoma antigen-encoding (MAGE) genes encode peptides which are expressed by a proportion of malignant melanomas (MMs) and can be recognized in vitro by autologous cytolytic T lymphocytes in a human leucocyte-associated antigen (HLA)-restricted manner. Although expression of MAGE genes has been stu
## Abstract Cytotoxic T lymphocytes (CTL) reactive with human melanoma tumor cells occasionally display crossβreactivity with normal melanocytes. Previously, we identified the melanocyte lineageβspecific antigen gp100 that is expressed by both melanoma cells and normal melanocytes, as a target anti
Vitiligo is a skin disorder characterized by depigmented macules secondary to melanocyte loss. An unusual facet is its relation to melanoma: Cytotoxic T lymphocytes directed to melanocyte antigens are found in both conditions and imply a breakdown of tolerance, yet the resulting immune reaction is t
Peptides derived from melanocyte differentiation antigens have been identified as targets for MHC class I-restricted cytolytic T lymphocytes (CTLs) in human melanoma Regression of antigen-expressing tumors as well as selection of antigen-loss variants in the presence of antigen-specific CTLs have pr